Company profile
Cardax, Inc.
OTC: CDXI · Healthcare · Biotechnology
#933 of 1,422 Healthcare companies by revenue26th-percentile growth
EA Score
——FH —DQ 32GM —SS 29
v0.1 · 25/100 weight · pillars only
↑ listing tenure, Piotroski F · ↓ market scale, balance-sheet leverage
Methodology →Revenue TTM
$500.7k
Rev growth YoY (TTM)
-27.3%
Net income (FY)
-$5.1M
Employees
10
as of 2026-07-12
Market cap
$80
as of 2026-07-12
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$538.9k$538.9k2020
Net income-$5.1M-$5.1M2020
Operating income-$3.1M-$3.1M2020
Total assets$1.4M$1.4M2020
Liabilities$11.6M$11.6M2020
Equity-$10.2M-$10.2M2020
Revenue trend
FY2013 – FY2020 · USD
FY13
FY12
FY13
FY16
FY18
FY18
FY19
FY20
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Cardax, Inc.’s revenue?
Cardax, Inc. booked $538.9k in FY2020 revenue, contracting 24% year over year — slower than 74% of Healthcare companies we track, at a -938.0% net margin.
Peers · Healthcare
VYNE Therapeutics Inc.38DTrevena, Inc.——Solana Company49DLipella Pharmaceuticals Inc.——Sibannac, Inc.——Medivolve Inc.——Neighbors
Honolulu →Key facts
CEODavid G. Watumull
SectorHealthcare
IndustryBiotechnology
HeadquartersHonolulu, HI
ExchangeOTC: CDXI
Employees10
IPO date2013-03-06
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.